Role of nucleic acid testing in cadaver organ donor screening: Detection of hepatitis C virus RNA in seropositive and seronegative donors

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 627-634

  Aswad, S ^a   Khan, N S ^b   Comanor, Lorraine ^c   Chinchilla, C ^a   Corado, L ^a   Mone, T ^c   Mendez, R ^a  

^a National Institute of Transplantation Los Angeles   (United States)

^b Amber Institute   (United States)

^c One Legacy ^*  (United States)

Author keywords

Cadaver organ donors; Nucleic acid tests; Screening diagnostic algorithm; Serologic tests; Transcription mediated amplification

Indexed keywords

HEPATITIS C ANTIBODY; NUCLEIC ACID; VIRUS RNA;

ANTIBODY DETECTION; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SAMPLING; SCREENING; SEROLOGY; VIRUS DETECTION;

ALGORITHMS; CADAVER; DONOR SELECTION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; TISSUE DONORS; TRANSCRIPTION, GENETIC;

EID: 27444446838     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00632.x     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. Hepatitis C virus transmission from an antibody-negative organ and tissue donor - United States, 2000-2002. JAMA 2003; 289: 3235-3236.
2. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-487.
3. Stanworth SJ, Warwick RM, Ferguson M, Barbara JA. A UK survey of virological testing of cadaver tissue donors. Microbiology Working Group of the NIBSC steering group on Tissue/Cell Banking and Engineering. Vox Sang 2000; 79: 227-230.
4. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351: 751-759.
5. Younossi ZM. Chronic hepatitis C: a clinical overview. Cleve Clin J Med 1997; 64: 259-268.
6. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003; 36: 47-53.
7. Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000; 31: 781-786.
8. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8: 200-206.
9. Tobler LH, Stramer SL, Lee SR et al. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion 2003; 43: 1452-1459.
10. Krajden M. Hepatitis C virus diagnosis and testing. Can J Public Health 2000; 91(Suppl. 1): S34-39.
11. Pereira BJ, Levey AS. Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste. Pediatr Nephrol 1995; 9(Suppl.): S23-28.
12. Pereira BJ, Wright TL, Schmid CH et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994; 46: 886-892.
13. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004; 364: 1611-1612.
14. Krajden M, Shivji R, Gunadasa K et al. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol 2004; 42: 4054-4059.
15. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-768.
16. U.S. Food and Drug Administration. Draft Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). available at http://www.fda.gov/cber/gdlns/ tissdonor.pdf May 25, 2004.
17. Gorrin G, Friesenhahn M, Lin P et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Microbiol 2003; 41: 310-317.
18. Krajden M, Ziermann R, Khan A et al. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol 2002; 40: 2903-2907.
19. Beld M, Robbers S, Dijkman-de Haan K, Weel J, Sol C, Boom R. Clinical utility of Bayer VERSANT HCV RNA Qualitative (TMA) assay above Roche COBAS AMPLICOR 2.0 assay for detection of HCV RNA in EDTA plasma from dialysis patients. Hepatology 2001; 34: 227A.
20. Beld M, Sentjens R, Rebers S et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002; 40: 788-793.
21. Khan N, Aswad S, Shidban H, Aghajani M, Mendez R, Comanor L. Improved detection of HCV Infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. J Clin Virol 2004; 30: 175-182.
22. Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003; 41: 651-656.
23. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 818-823.
24. Comanor L, Anderson F, Ghany M et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001; 96: 2968-2972.
25. Padley DJ, Lucas SB, Saldanha J. Elimination of false-negative hepatitis C virus RNA results by removal of inhibitors in cadaver-organ donor blood specimens. Transplantation 2003; 76: 432-434.
26. Elbeik T, Surtihadi J, Destree M et al. Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42: 563-569.
27. Comanor L, Elkin C, Leung K et al. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. J Clin Virol 2003; 28: 14-26.
28. Natov SN, Pereira BJC. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 2: hepatitis C virus). Transpl Infect Dis 2002; 4: 124-131.
29. Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-184.
30. Pereira BJ, Milford EL, Kirkman RL et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327: 910-915.
31. Hepatitis C virus (HCV); other specified viral hepatitis without mention of hepatic coma. Timely Data Resources. Retrieved November 12, 2004.
32. U.S. Food and Drug Administration. Product Approval Information. available at http://www.fda.gov/cber/approvltr/hivhcvgen060404L.htm June 4, 2004.
33. Beld M, Penning M, van Putten M et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183-1191.
34. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
35. Durand F, Danic B, Tardivel R et al. Discovery of a chronic HVC infection without seroconversion in a blood donor in France during 28 months. Transfus Clin Biol 2000; 7: 242-250.
36. Arrojo IP, Pareja MO, Orta MD et al. Detection of a healthy carrier of HCV with no evidence of antibodies for over four years. Transfusion 2003; 43: 953-957.
37. Heim A, Wagner D, Rothamel T, Hartmann U, Flik J, Verhagen W. Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 1999; 58: 291-295.
38. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-463.
39. Bucci JR, Matsumoto CS, Swanson SJ et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-2982.
40. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315: 333-337.
41. Operskalski EA, Mosley JW, Tobler LH et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003; 43: 1433-1441.
42. Nubling CM, Unger G, Chudy M, Raia S, Lower J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002; 42: 1037-1045.
43. Peterson J, Green G, Iida K et al. Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection. Vox Sang 2000; 78: 80-85.